India, April 24 -- The U.S. Food and Drug Administration has rolled out a plan to speed up the development of psychedelic treatments for serious mental health issues, marking a significant change in U.S. healthcare policy.
This move follows an executive order from Donald Trump, which urged federal health agencies to broaden access to new therapies. The focus is on tough-to-treat conditions like treatment-resistant depression, PTSD, and substance use disorders.
Robert F. Kennedy Jr. mentioned that the administration is putting a spotlight on therapies that get the "Breakthrough Therapy" designation, which means there's early clinical evidence showing real improvements for patients. As part of the initiative, the FDA will be giving out nati...